论文部分内容阅读
目的:评价3种治疗下呼吸道感染用药方案的治疗效果和药物经济学效果。方法:运用成本-效果分析法对3种治疗方案的治疗成本与治疗效果进行分析评价。结果:A、B两组间治疗效果、总成本及成本-效果比没有显著差异,但分别与C组间有显著差异(P<0.05)。结论:从经济学角度而言,A组成本/效果比最低为最佳治疗方案,但安全性、疗效也低;考虑到患者生命质量、不良反应发生率、间接医疗成本等因素,C组虽成本最高但疗效高、疗程短、安全性好,并能显著提高病人的生命质量。
Objective: To evaluate the therapeutic effects and pharmacological effects of three kinds of drugs for treating lower respiratory tract infection. Methods: The cost-effectiveness analysis was used to analyze and evaluate the treatment costs and treatment effects of the three treatment regimens. Results: There was no significant difference in the treatment effect, total cost and cost-effectiveness between group A and group B, but there was significant difference between group A and group B (P <0.05). Conclusion: From an economic point of view, the lowest cost / benefit ratio of group A is the best treatment, but the safety and curative effect are also low. Considering factors such as patient quality of life, incidence of adverse reactions, and indirect medical costs, The highest cost but high efficacy, short course, good safety, and can significantly improve the quality of life of patients.